BR0111264A - Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização - Google Patents

Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização

Info

Publication number
BR0111264A
BR0111264A BR0111264-3A BR0111264A BR0111264A BR 0111264 A BR0111264 A BR 0111264A BR 0111264 A BR0111264 A BR 0111264A BR 0111264 A BR0111264 A BR 0111264A
Authority
BR
Brazil
Prior art keywords
factor viia
compounds
formula
derivatives
preparation
Prior art date
Application number
BR0111264-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Otmar Klingler
Manfred Schudok
Hans-Peter Nestler
Hans Matter
Herman Schreuder
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0111264A publication Critical patent/BR0111264A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18Ethylenedioxybenzenes, not substituted on the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR0111264-3A 2000-06-06 2001-05-26 Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização BR0111264A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00112116A EP1162194A1 (en) 2000-06-06 2000-06-06 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
PCT/EP2001/006029 WO2001094301A2 (en) 2000-06-06 2001-05-26 Factor viia inhibitory (thio)urea derivatives, their preparation and their use

Publications (1)

Publication Number Publication Date
BR0111264A true BR0111264A (pt) 2003-06-17

Family

ID=8168926

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111264-3A BR0111264A (pt) 2000-06-06 2001-05-26 Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização

Country Status (29)

Country Link
US (1) US6743790B2 (enExample)
EP (2) EP1162194A1 (enExample)
JP (1) JP4809570B2 (enExample)
KR (1) KR101011345B1 (enExample)
CN (1) CN1208314C (enExample)
AR (1) AR030936A1 (enExample)
AU (2) AU7749401A (enExample)
BR (1) BR0111264A (enExample)
CA (1) CA2410862C (enExample)
CZ (1) CZ20023963A3 (enExample)
DE (1) DE60139320D1 (enExample)
DK (1) DK1299354T3 (enExample)
EE (1) EE200200617A (enExample)
ES (1) ES2330412T3 (enExample)
HR (1) HRP20020961A2 (enExample)
HU (1) HUP0301631A2 (enExample)
IL (2) IL153220A0 (enExample)
MX (1) MXPA02009789A (enExample)
MY (1) MY129363A (enExample)
NO (1) NO328546B1 (enExample)
NZ (1) NZ522960A (enExample)
PL (1) PL359584A1 (enExample)
PT (1) PT1299354E (enExample)
RU (1) RU2286337C2 (enExample)
SK (1) SK17032002A3 (enExample)
TW (1) TWI283662B (enExample)
WO (1) WO2001094301A2 (enExample)
YU (1) YU89202A (enExample)
ZA (1) ZA200209018B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183277B2 (en) 2002-04-27 2007-02-27 Merck Patent Gmbh Carboxylic acid amides
US7122580B2 (en) * 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
WO2004113316A1 (en) * 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
US7250447B2 (en) * 2003-05-20 2007-07-31 Genentech, Inc. Acylsulfamide inhibitors of factor VIIa
WO2005014533A2 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2006041119A1 (ja) * 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. ヒドラジド誘導体
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JP2008531525A (ja) * 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Vii因子ポリペプチド製剤を安定化する化合物
EP1856037A1 (en) * 2005-02-24 2007-11-21 Novo Nordisk Health Care AG Amidino-compounds for stabilizing factor vii polypeptide formulations
US20080312161A1 (en) * 2005-02-24 2008-12-18 Anders Klarskov Petersen Compounds For Stabilizing Factor VII Polypeptide Formulations
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CA2647423C (en) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Triazolone derivative
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009038157A1 (ja) 2007-09-21 2009-03-26 Eisai R & D Management Co., Ltd. 2,3-ジヒドロ-イミノイソインドール誘導体
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
PT2770989T (pt) 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
WO2013158597A1 (en) * 2012-04-16 2013-10-24 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
EP2906236A1 (en) * 2012-10-10 2015-08-19 Novo Nordisk Health Care AG Liquid pharmaceutical composition of factor vii polypeptide
RU2663911C2 (ru) 2013-03-06 2018-08-13 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз
CA2899804A1 (en) 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
EP0570507A4 (en) * 1991-02-05 1994-09-21 Smithkline Beecham Corp Anti-aggregatory peptides containing an aromatic ester or amide
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
JP3387948B2 (ja) * 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) * 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313269D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Allophanic acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists
AU7862794A (en) * 1993-10-19 1995-05-08 Sumitomo Pharmaceuticals Company, Limited 2,3-diaminopropionic acid derivative
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
CA2243507A1 (en) * 1996-01-30 1997-08-07 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
PL192083B1 (pl) * 1997-11-18 2006-08-31 Dupont Pharmaceuticals Res Lab Pochodne amin cyklicznych i ich zastosowanie
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
DK1299354T3 (da) 2009-11-16
US6743790B2 (en) 2004-06-01
JP2003535844A (ja) 2003-12-02
AR030936A1 (es) 2003-09-03
CN1427818A (zh) 2003-07-02
MY129363A (en) 2007-03-30
US20020052417A1 (en) 2002-05-02
IL153220A0 (en) 2003-07-06
PL359584A1 (en) 2004-08-23
NO328546B1 (no) 2010-03-15
CA2410862C (en) 2009-11-10
KR101011345B1 (ko) 2011-01-28
TWI283662B (en) 2007-07-11
CZ20023963A3 (cs) 2003-03-12
MXPA02009789A (es) 2003-03-12
AU7749401A (en) 2001-12-17
WO2001094301A3 (en) 2002-04-04
YU89202A (sh) 2006-05-25
NZ522960A (en) 2004-05-28
NO20025810L (no) 2002-12-03
EP1162194A1 (en) 2001-12-12
ZA200209018B (en) 2003-10-08
RU2286337C2 (ru) 2006-10-27
JP4809570B2 (ja) 2011-11-09
WO2001094301A2 (en) 2001-12-13
DE60139320D1 (de) 2009-09-03
PT1299354E (pt) 2009-10-01
EP1299354B1 (en) 2009-07-22
CN1208314C (zh) 2005-06-29
HK1055941A1 (en) 2004-01-30
SK17032002A3 (sk) 2003-05-02
CA2410862A1 (en) 2001-12-13
AU2001277494B2 (en) 2006-05-04
ES2330412T3 (es) 2009-12-10
KR20030007911A (ko) 2003-01-23
EP1299354A2 (en) 2003-04-09
NO20025810D0 (no) 2002-12-03
IL153220A (en) 2008-11-03
HUP0301631A2 (hu) 2003-09-29
HRP20020961A2 (en) 2004-12-31
EE200200617A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
YU89202A (sh) Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba
PT1349847E (pt) Novos derivados de oxibenzamidas como inibidores do factor xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
UY28325A1 (es) Nuevos derivados de indol como inhibidores del factor xa
DK1423357T3 (da) Urinstofderivater med antiproteolytisk aktivitet
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
BR0011461A (pt) Inibidores do fator viia
BR0012610A (pt) Novo derivado de difenilpiperidina
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
TR199801229T2 (xx) ''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri
EP0620737B1 (en) Use of LACTOFERRIN iN the manufacture of a medicament for treating RHEUMATISM
BRPI0410446A (pt) derivados de benzimidazol como inibidores de fator xa
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
US2491489A (en) Therapeutic composition of sulfonamides
JPS61277614A (ja) 抗プラスミン剤

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time